A
367.60
-11.67 (-3.08%)
| Penutupan Terdahulu | 379.27 |
| Buka | 375.18 |
| Jumlah Dagangan | 2,592,566 |
| Purata Dagangan (3B) | 2,888,240 |
| Modal Pasaran | 198,161,268,736 |
| Harga / Pendapatan (P/E TTM) | 25.83 |
| Harga / Pendapatan (P/E Ke hadapan) | 17.18 |
| Harga / Jualan (P/S) | 5.57 |
| Harga / Buku (P/B) | 23.51 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 30 Apr 2026 |
| Hasil Dividen (DY TTM) | 2.63% |
| Margin Keuntungan | 17.39% |
| Margin Operasi (TTM) | 28.73% |
| EPS Cair (TTM) | 10.97 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 9.40% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -18.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 924.46% |
| Nisbah Semasa (MRQ) | 1.17 |
| Aliran Tunai Operasi (OCF TTM) | 12.19 B |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 13.09 B |
| Pulangan Atas Aset (ROA TTM) | 7.04% |
| Pulangan Atas Ekuiti (ROE TTM) | 105.67% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - General (US) | Menaik | Bercampur |
| Drug Manufacturers - General (Global) | Menaik | Bercampur | |
| Stok | Amgen Inc. | Menaik | Menaik |
AISkor Stockmoo
-1.1
| Konsensus Penganalisis | -1.5 |
| Aktiviti Orang Dalam | 0.0 |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | -1.5 |
| Osilator Teknikal | 0.5 |
| Purata | -1.10 |
|
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - General |
| Gaya Pelaburan | Large Value |
| % Dimiliki oleh Orang Dalam | 0.21% |
| % Dimiliki oleh Institusi | 83.77% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 432.00 (Piper Sandler, 17.52%) | Beli |
| Median | 350.00 (-4.79%) | |
| Rendah | 309.00 (Morgan Stanley, -15.94%) | Pegang |
| Purata | 358.23 (-2.55%) | |
| Jumlah | 4 Beli, 9 Pegang | |
| Harga Purata @ Panggilan | 364.76 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Jefferies | 10 Mar 2026 | 350.00 (-4.79%) | Pegang | 367.60 |
| Barclays | 20 Feb 2026 | 350.00 (-4.79%) | Pegang | 374.75 |
| Wells Fargo | 19 Feb 2026 | 375.00 (2.01%) | Pegang | 375.50 |
| Piper Sandler | 18 Feb 2026 | 432.00 (17.52%) | Beli | 379.73 |
| Argus Research | 06 Feb 2026 | 400.00 (8.81%) | Beli | 384.32 |
| Guggenheim | 06 Feb 2026 | 347.00 (-5.60%) | Pegang | 384.32 |
| Cantor Fitzgerald | 04 Feb 2026 | 350.00 (-4.79%) | Pegang | 366.20 |
| Citigroup | 04 Feb 2026 | 345.00 (-6.15%) | Pegang | 366.20 |
| Leerink Partners | 04 Feb 2026 | 355.00 (-3.43%) | Beli | 366.20 |
| Morgan Stanley | 04 Feb 2026 | 309.00 (-15.94%) | Pegang | 366.20 |
| UBS | 26 Jan 2026 | 390.00 (6.09%) | Beli | 349.69 |
| 07 Jan 2026 | 380.00 (3.37%) | Beli | 341.64 | |
| Bernstein | 20 Jan 2026 | 335.00 (-8.87%) | Pegang | 331.00 |
| Truist Securities | 08 Jan 2026 | 319.00 (-13.22%) | Pegang | 330.11 |
| Papar semua | ||||
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| BRADWAY ROBERT A | 377.00 | 379.27 | -41,628 | -15,885,083 |
| BUSCH MATTHEW C. | 377.00 | - | 938 | 353,626 |
| GORDON MURDO | 377.00 | - | 13,403 | 5,052,931 |
| GRAHAM JONATHAN P | 377.00 | - | 10,723 | 4,042,571 |
| GRIFFITH PETER H. | 377.00 | - | 12,063 | 4,547,751 |
| GRYGIEL NANCY A. | 377.00 | - | 2,010 | 757,770 |
| KHOSLA RACHNA | 377.00 | - | 1,876 | 707,252 |
| MILLER DEREK | 377.00 | - | 3,484 | 1,313,468 |
| REESE DAVID M | 377.00 | - | 12,063 | 4,547,751 |
| SANTOS ESTEBAN | 377.00 | - | 11,259 | 4,244,643 |
| Jumlah Keseluruhan Kuantiti Bersih | 26,191 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 9,682,680 | |||
| Purata Pembelian Keseluruhan ($) | 377.00 | |||
| Purata Jualan Keseluruhan ($) | 379.27 | |||
| Julat Insider ($) | ||||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| BRADWAY ROBERT A | Pegawai | 04 Mar 2026 | Dibuang (-) | 84,285 | 379.27 | 31,966,772 |
| BRADWAY ROBERT A | Pegawai | 04 Mar 2026 | Pelaksanaan pilihan | 119,782 | - | - |
| BUSCH MATTHEW C. | Pegawai | 03 Mar 2026 | Diperolehi (+) | 938 | 377.00 | 353,626 |
| BRADWAY ROBERT A | Pegawai | 03 Mar 2026 | Diperolehi (+) | 42,657 | 377.00 | 16,081,689 |
| GORDON MURDO | Pegawai | 03 Mar 2026 | Diperolehi (+) | 13,403 | 377.00 | 5,052,931 |
| GRAHAM JONATHAN P | Pegawai | 03 Mar 2026 | Diperolehi (+) | 10,723 | 377.00 | 4,042,571 |
| GRIFFITH PETER H. | Pegawai | 03 Mar 2026 | Diperolehi (+) | 12,063 | 377.00 | 4,547,751 |
| GRYGIEL NANCY A. | Pegawai | 03 Mar 2026 | Diperolehi (+) | 2,010 | 377.00 | 757,770 |
| KHOSLA RACHNA | Pegawai | 03 Mar 2026 | Diperolehi (+) | 1,876 | 377.00 | 707,252 |
| MILLER DEREK | Pegawai | 03 Mar 2026 | Diperolehi (+) | 3,484 | 377.00 | 1,313,468 |
| REESE DAVID M | Pegawai | 03 Mar 2026 | Diperolehi (+) | 12,063 | 377.00 | 4,547,751 |
| SANTOS ESTEBAN | Pegawai | 03 Mar 2026 | Diperolehi (+) | 11,259 | 377.00 | 4,244,643 |
| Papar semua | ||||||
| Tarikh | Jenis | Butiran |
|---|---|---|
| 03 Feb 2026 | Pengumuman | AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS |
| 28 Jan 2026 | Pengumuman | AMGEN ANNOUNCES WEBCAST OF 2025 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS |
| 20 Jan 2026 | Pengumuman | Nonprofit Health Services Organization Files Lawsuit Against Fortune 500 Pharmaceutical Company Over Prescription Drug Access |
| 07 Jan 2026 | Pengumuman | AMGEN TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE |
| 06 Jan 2026 | Pengumuman | AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE |
| 19 Dec 2025 | Pengumuman | AMGEN TAKES ACTION WITH THE U.S. GOVERNMENT TO LOWER THE COST OF MEDICINES FOR AMERICAN PATIENTS |
| 19 Dec 2025 | CNBC | Nine of the largest pharma companies ink deals with Trump to lower drug prices |
| Hasil Dividen (DY TTM) | 2.63% |
| Purata Hasil Dividen 5T | 3.08% |
| Nisbah Pembayaran | 83.23% |
| Jangkaan Pembayaran Dividen Seterusnya | Jun 2026 |
| Tarikh EX | Tarikh Pengumuman | Tarikh Pembayaran | Perincian |
|---|---|---|---|
| 13 Feb 2026 | 09 Dec 2025 | 06 Mar 2026 | 2.52 Tunai |
| 21 Nov 2025 | 31 Oct 2025 | 12 Dec 2025 | 2.38 Tunai |
| 22 Aug 2025 | 01 Aug 2025 | 12 Sep 2025 | 2.38 Tunai |
| 16 May 2025 | 04 Mar 2025 | 06 Jun 2025 | 2.38 Tunai |
| 14 Feb 2025 | 10 Dec 2024 | 07 Mar 2025 | 2.38 Tunai |
| 18 Nov 2024 | 25 Oct 2024 | 09 Dec 2024 | 2.25 Tunai |
| 16 Aug 2024 | 02 Aug 2024 | 06 Sep 2024 | 2.25 Tunai |
| 16 May 2024 | 06 Mar 2024 | 07 Jun 2024 | 2.25 Tunai |
| 15 Feb 2024 | 12 Dec 2023 | 07 Mar 2024 | 2.25 Tunai |
| 16 Nov 2023 | 24 Oct 2023 | 08 Dec 2023 | 2.13 Tunai |
| 17 Aug 2023 | 01 Aug 2023 | 08 Sep 2023 | 2.13 Tunai |
| 17 May 2023 | 07 Mar 2023 | 08 Jun 2023 | 2.13 Tunai |
| 14 Feb 2023 | 12 Dec 2022 | 08 Mar 2023 | 2.13 Tunai |
| 16 Nov 2022 | 28 Oct 2022 | 08 Dec 2022 | 1.94 Tunai |
| 17 Aug 2022 | 03 Aug 2022 | 08 Sep 2022 | 1.94 Tunai |
| 16 May 2022 | 02 Mar 2022 | 08 Jun 2022 | 1.94 Tunai |
| 14 Feb 2022 | 03 Dec 2021 | 08 Mar 2022 | 1.94 Tunai |
| 15 Nov 2021 | 21 Oct 2021 | 08 Dec 2021 | 1.76 Tunai |
| 16 Aug 2021 | 30 Jul 2021 | 08 Sep 2021 | 1.76 Tunai |
| 14 May 2021 | 03 Mar 2021 | 08 Jun 2021 | 1.76 Tunai |
| 11 Feb 2021 | 16 Dec 2020 | 08 Mar 2021 | 1.76 Tunai |
| 13 Nov 2020 | 21 Oct 2020 | 08 Dec 2020 | 1.6 Tunai |
| 14 Aug 2020 | 23 Jul 2020 | 08 Sep 2020 | 1.6 Tunai |
| 15 May 2020 | 04 Mar 2020 | 08 Jun 2020 | 1.6 Tunai |
| 13 Feb 2020 | 11 Dec 2019 | 06 Mar 2020 | 1.6 Tunai |
| 14 Nov 2019 | 22 Oct 2019 | 06 Dec 2019 | 1.45 Tunai |
| 14 Aug 2019 | 02 Aug 2019 | 06 Sep 2019 | 1.45 Tunai |
| 16 May 2019 | 07 Mar 2019 | 07 Jun 2019 | 1.45 Tunai |
| 14 Feb 2019 | 07 Dec 2018 | 08 Mar 2019 | 1.45 Tunai |
| 15 Nov 2018 | 23 Oct 2018 | 07 Dec 2018 | 1.32 Tunai |
| 16 Aug 2018 | 31 Jul 2018 | 07 Sep 2018 | 1.32 Tunai |
| 16 May 2018 | 07 Mar 2018 | 08 Jun 2018 | 1.32 Tunai |
| 14 Feb 2018 | 12 Dec 2017 | 08 Mar 2018 | 1.32 Tunai |
| 16 Nov 2017 | 24 Oct 2017 | 08 Dec 2017 | 1.15 Tunai |
| 15 Aug 2017 | 28 Jul 2017 | 08 Sep 2017 | 1.15 Tunai |
| 15 May 2017 | 07 Mar 2017 | 08 Jun 2017 | 1.15 Tunai |
| 13 Feb 2017 | 20 Dec 2016 | 08 Mar 2017 | 1.15 Tunai |
| 14 Nov 2016 | 14 Oct 2016 | 08 Dec 2016 | 1 Tunai |
| 15 Aug 2016 | 22 Jul 2016 | 08 Sep 2016 | 1 Tunai |
| 13 May 2016 | 02 Mar 2016 | 08 Jun 2016 | 1 Tunai |
| 11 Feb 2016 | 15 Dec 2015 | 08 Mar 2016 | 1 Tunai |
| 12 Nov 2015 | 14 Oct 2015 | 07 Dec 2015 | 0.79 Tunai |
| 13 Aug 2015 | 28 Jul 2015 | 08 Sep 2015 | 0.79 Tunai |
| 12 May 2015 | 04 Mar 2015 | 05 Jun 2015 | 0.79 Tunai |
| 10 Feb 2015 | 17 Dec 2014 | 06 Mar 2015 | 0.79 Tunai |
| 10 Nov 2014 | 17 Oct 2014 | 05 Dec 2014 | 0.61 Tunai |
| 12 Aug 2014 | 25 Jul 2014 | 05 Sep 2014 | 0.61 Tunai |
| 13 May 2014 | 05 Mar 2014 | 06 Jun 2014 | 0.61 Tunai |
| 11 Feb 2014 | 13 Dec 2013 | 07 Mar 2014 | 0.61 Tunai |
| 12 Nov 2013 | 16 Oct 2013 | 06 Dec 2013 | 0.47 Tunai |
| 14 Aug 2013 | 26 Jul 2013 | 06 Sep 2013 | 0.47 Tunai |
| 14 May 2013 | 06 Mar 2013 | 07 Jun 2013 | 0.47 Tunai |
| 11 Feb 2013 | 13 Dec 2012 | 07 Mar 2013 | 0.47 Tunai |
| Papar semua | |||
Hasil Dividen Tahunan
| Tahun | Dividen Tahunan ($) | Kekerapan/Tahun | Hasil % |
|---|---|---|---|
| 2026 | 2.52 | 1 | 0.69 |
| 2025 | 9.52 | 4 | 2.91 |
| 2024 | 9.00 | 4 | 3.45 |
| 2023 | 8.52 | 4 | 2.96 |
| 2022 | 7.76 | 4 | 2.96 |
| 2021 | 7.04 | 4 | 3.13 |
| 2020 | 6.40 | 4 | 2.78 |
| 2019 | 5.80 | 4 | 2.41 |
| 2018 | 5.28 | 4 | 2.71 |
| 2017 | 4.60 | 4 | 2.65 |
| 2016 | 4.00 | 4 | 2.74 |
| 2015 | 3.16 | 4 | 1.95 |
| 2014 | 2.44 | 4 | 1.53 |
| 2013 | 1.88 | 4 | 1.65 |
| Papar semua | |||
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |